A phase IIb trial of BMN 270 in patiens with hemophilia A
Latest Information Update: 10 Jan 2017
At a glance
- Drugs Valoctocogene-roxaparvovec (Primary)
- Indications Haemophilia A
- Focus Registrational; Therapeutic Use
- 08 Jan 2017 According to a BioMarin Pharmaceutical media release, this is a potentially registration enabling study.
- 08 Jan 2017 According to a BioMarin Pharmaceutical media release, this trial is expected to initiate in the third quarter of 2017.
- 04 Aug 2016 New trial record